Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immediate Versus Deferred Cytoreductive Nephrectomy With Ipilimumab/Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma
NCT07233668Phase 3Not yet recruiting
- Sponsor
- Seoul National University Hospital
- Start
- Dec 2025
- Primary completion
- Oct 2028
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of ipilimumab, nivolumab in clear cell renal cell carcinoma (ccRCC), sponsored by Seoul National University Hospital. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
ipilimumabnivolumab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT07233668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07233668.